As I said previously, the specific virilizing side effects listed in the previous post are generally permanent and this a pretty well-established phenomenon even with clinical dosages which I know personally are equal to, even in the most responsible users, and far less than those who aren't responsible recreational users.
As you know, if trying to establish and confirm if something is irreversible or not in a study, a follow-up after cessation of use is performed, and it is for this very reason that the authors in these references conclude that they are permanent. Or, as you also know, in some of these clinical studies you have a few main authors who are collecting data from participating clinics throughout the US. This too is where it has been established, especially with oncologists who were using androgens in women, as these are not simply temporary subjects, but lifelong patients. It's very easy to give a follow-up in such cases. This is what has lead to the well-known Gilman's citation and of course from the product inserts themselves as the manufacturers are the first to state this. Even ignoring the clinical data, just from a logical standpoint, it wouldn't make sense for the manufacturer itself to state specifically that those effects are generally irreversible as that's certainly not going to help with sales when it comes to convincing the clinician and patient.
Clinically, stanozolol is typically administered at 2 mg, 3 times daily and 5-8 mg daily with oxandrolone (given as one dose). The following references are all supportive of the said side effects listed in the first post, being irreversible.
Again, the likelihood of experiencing virilizing side effects is dose and duration dependent, but again, to say these side effects are then completely reversible or that they usually subside, is not correct.
If there is data which contradicts this and that these side effects are reversible, I'd be interested in seeing it.
Scott MJ Jr & Scott MJ 3rd: Dermatologists and anabolic-androgenic drug abuse. CUTIS 1989; 44:30-35.
Strauss RH, Liggett MT & Lanese RR: Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA 1985; 253:2871-2873.
USPDI: Drug Information for the Health Care Professional, 8th ed. US Pharmacopeial Convention, Inc, Rockville, MD, 1988.
Product Information: Winstrol(R), stanozolol. Sanofi Pharmaceuticals, New York, NY, (PI revised 5/97) reviewed 5/2000.
Product Information: Oxandrin(R), oxandrolone. BTG Pharmaceuticals, Iselin, NJ, 1998.
AMA Department of Drugs: Drug Evaluations Subscription. American Medical Association, Chicago, IL, 1991.
Naeraa RW, Nielsen J, Pedersen IL et al: Effect of oxandrolone on growth and final height in Turner's syndrome. Acta Pediatr Scand 1990; 79:784-789.
Notter G: Treatment of disseminated carcinoma of the breast by metenolone enanthate. Acta Radiol Ther Physics Biol 1975; 14:545-551.
Schlesser JL (ed): Drugs Available Abroad. A Guide to Therapeutic Drugs Available and Approved Outside the U.S., 1st ed. Gale Research Inc., Detroit, MI; 1991:72-73.
Gilman AG, Rall TW, Nies AS et al (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Permagon Press, New York, NY, 1990.
Pain JA, Wickremesinghe SS & Bradbeer JW: Combined tamoxifen and anabolic steroid as primary treatment for breast carcinoma in the elderly. Eur J Surg Oncol 1990; 16:225-228.